Sarepta Therapeutics (SRPT) Competitors $106.28 -2.13 (-1.96%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$106.22 -0.06 (-0.06%) As of 02/21/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SRPT vs. ARGX, BNTX, ONC, TEVA, SMMT, GMAB, ITCI, VTRS, MRNA, and RDYShould you be buying Sarepta Therapeutics stock or one of its competitors? The main competitors of Sarepta Therapeutics include argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Sarepta Therapeutics vs. argenx BioNTech Beigene Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Sarepta Therapeutics (NASDAQ:SRPT) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends. Do institutionals and insiders believe in SRPT or ARGX? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 60.3% of argenx shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by insiders. Comparatively, 2.4% of argenx shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has preferable earnings and valuation, SRPT or ARGX? argenx has higher revenue and earnings than Sarepta Therapeutics. argenx is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.24B8.16-$535.98M$1.2585.02argenx$1.27B30.87-$295.05M-$0.88-732.36 Do analysts recommend SRPT or ARGX? Sarepta Therapeutics currently has a consensus target price of $176.77, indicating a potential upside of 66.33%. argenx has a consensus target price of $658.39, indicating a potential upside of 2.16%. Given Sarepta Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Sarepta Therapeutics is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 1 Sell rating(s) 2 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 2.87argenx 1 Sell rating(s) 2 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.86 Is SRPT or ARGX more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to argenx's net margin of -2.11%. Sarepta Therapeutics' return on equity of 11.00% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% argenx -2.11%-1.45%-1.29% Which has more volatility & risk, SRPT or ARGX? Sarepta Therapeutics has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Does the MarketBeat Community favor SRPT or ARGX? Sarepta Therapeutics received 817 more outperform votes than argenx when rated by MarketBeat users. Likewise, 75.23% of users gave Sarepta Therapeutics an outperform vote while only 67.19% of users gave argenx an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes146475.23% Underperform Votes48224.77% argenxOutperform Votes64767.19% Underperform Votes31632.81% Does the media favor SRPT or ARGX? In the previous week, Sarepta Therapeutics had 4 more articles in the media than argenx. MarketBeat recorded 14 mentions for Sarepta Therapeutics and 10 mentions for argenx. Sarepta Therapeutics' average media sentiment score of 1.12 beat argenx's score of 1.04 indicating that Sarepta Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive argenx 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySarepta Therapeutics beats argenx on 15 of the 18 factors compared between the two stocks. Get Sarepta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SRPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SRPT vs. The Competition Export to ExcelMetricSarepta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.36B$7.05B$5.84B$9.14BDividend YieldN/A2.75%4.75%3.85%P/E Ratio85.026.1126.7019.17Price / Sales8.16268.31435.2970.71Price / CashN/A65.6738.0134.83Price / Book11.566.707.644.62Net Income-$535.98M$138.98M$3.19B$246.06M7 Day Performance-1.55%-2.63%-2.12%-2.63%1 Month Performance-8.45%-2.33%-0.45%-2.15%1 Year Performance-21.15%-5.33%16.26%12.88% Sarepta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SRPTSarepta Therapeutics4.4998 of 5 stars$106.28-2.0%$176.77+66.3%-19.7%$10.36B$1.24B85.021,314Upcoming EarningsARGXargenx2.5004 of 5 stars$639.41-1.8%$658.39+3.0%+61.1%$38.85B$1.27B-726.601,148News CoveragePositive NewsBNTXBioNTech2.4325 of 5 stars$119.83-2.4%$142.72+19.1%+29.4%$28.73B$4.13B-57.066,133Positive NewsONCBeigeneN/A$230.86+2.4%N/AN/A$22.56B$2.46B-28.0210,600Insider TradeNews CoverageGap UpTEVATeva Pharmaceutical Industries2.8895 of 5 stars$16.24-2.4%$23.57+45.2%+28.8%$18.39B$16.54B-11.2037,851SMMTSummit Therapeutics2.3117 of 5 stars$21.37-2.1%$33.57+57.1%+438.2%$15.76B$700,000.00-76.32110GMABGenmab A/S4.5905 of 5 stars$21.30+1.8%$42.17+98.0%-22.8%$14.10B$2.39B20.682,204ITCIIntra-Cellular Therapies3.8866 of 5 stars$127.82-0.2%$103.62-18.9%+75.5%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.0155 of 5 stars$10.80flat$13.67+26.5%-15.2%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7334 of 5 stars$32.99+3.4%$66.89+102.8%-59.4%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories3.0362 of 5 stars$13.60-2.8%$17.00+25.0%-11.9%$11.35B$311.31B21.6527,048 Related Companies and Tools Related Companies argenx Competitors BioNTech Competitors Beigene Competitors Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Intra-Cellular Therapies Competitors Viatris Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SRPT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | Sponsored$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a porti...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored2025 AI Blueprint features Nvidia’s march to $5 trillionNvidia is now one of the most valuable companies in the world. It currently ranks second, just behind Apple...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sarepta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sarepta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
